Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12115198

    Microbials for animals

    MICROBIAL DISCOVERY GROUP, LLC · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12115166

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12116343

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12115255

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12116416

    Targeting intracellular target-binding determinants with intracellular antibodies

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12116423

    Ang (1-7) derivative oligopeptides and methods for using and producing the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12116374

    Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

    ACTUATE THERAPEUTICS INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12116461

    Host-guest interactions for pa superstructure formation

    Northwestern University · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12116574

    Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)

    Northwestern University · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12116589

    Treatment of amyotrophic lateral sclerosis (ALS)

    VOYAGER THERAPEUTICS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12116596

    Method and apparatus for improved mesenchymal stem cell harvesting

    Elite IP, LLC · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12116606

    Complement factor I-related compositions and methods

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12116637

    Compositions and methods for detecting and treating high grade subtypes of uterine cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12116635

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12115156

    Compositions of CXCR4 inhibitors and methods of preparation and use

    X4 Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12115216

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12116405

    Arthritis treatment

    XBIOTECH INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2024216080

    RÉGIMES IMMUNOSUPPRESSEURS ET PROCÉDÉS ASSOCIÉS

    BIOGEN MA INC [US] · Granted Thu Oct 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12122837

    Oncostatin M receptor antigen binding proteins

    Kiniksa Pharmaceuticals, GmbH · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12121524

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12121828

    Systems and methods of isolation of gallium-68

    Telix ARTMS Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12123036

    Soluble ACE2 variants and uses therefor

    Northwestern University · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12122998

    Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

    CRISPR THERAPEUTICS AG · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12123002

    Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

    VOYAGER THERAPEUTICS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12122773

    Crystalline hydrate of a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12122811

    BDNF mimetic peptide amphiphiles

    Northwestern University · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12122815

    GIP receptor agonist peptide compounds and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12122846

    Chimeric antigen receptor for tumor targeting

    Fate Therapeutics, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12122843

    High affinity monoclonal antibodies targeting glypican-1 and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12121580

    Antibacterial photodynamic therapy using copper-cysteamine nanoparticles

    The Board of Regents of the University of Texas System · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12121571

    Recombinant L-asparaginase

    Jazz Pharmaceuticals Ireland Limited · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12121608

    Biodegradable implant for sustained trans-nasal delivery of therapeutic agents to the brain

    Northwestern University · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12121526

    Targeting NCCA-ATP channel for organ protection following ischemic episode

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12121542

    BCMA chimeric antigen receptor based on single domain antibody and use thereof

    SHENZHEN PREGENE BIOPHARMA CO., LTD. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12121532

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Sarepta Therapeutics, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12121503

    Antiviral treatments

    BioCryst Pharmaceuticals, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12121288

    Combination tumor treatment

    Regents of the University of Minnesota · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12121567

    Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase

    Regents of the University of Minnesota · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    NURIX THERAPEUTICS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12121523

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12121522

    Methods of treating cancer with an mTOR inhibitor

    Revolution Medicines, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12123015

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12121569

    Methods and compositions for CNS delivery of iduronate-2-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12121525

    Methods for treating GI syndrome and graft versus host disease

    The Board of Regents of the University of Texas System · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12123012

    Methods and compositions for nucleic acid and protein payload delivery

    LIGANDAL, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12123035

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.